Methods of attenuating drug excipient cross reactivity
AssigneeChesapeake Therapeutics, LLC
InventorsRobb Lawrence, Robert E Bakin
Life of this patent
Estimating the term…
Abstract
The present application relates generally to novel pharmaceutical drug formulations comprising modified chemical compositions having reduced capacity for excipient mediated cross reactivity. Methods for their use and methods for identifying excipient related incompatibilities and/or adverse events are also disclosed.
Claims50
Excipient reduced pharmaceutical drug formulations obtained by:
- (i) comparing excipient profiles from two or more co-administered solid drug formulations, (ii) identifying the excipient or excipients common to said two or more co-administered solid drug formulations, (iii) reformulating one or more of said co-administered solid drug formulations without the excipient or excipients common to said two or more co-administered drug formulations.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of identifying an excipient or excipients contributing to adverse events in an individual comprising comparing adverse events associated with co-administration of two or more drug pharmaceutical formulations having at least one common excipient to the adverse events associated with co-administration of two or more drug pharmaceutical formulations lacking said common excipient.
A method of identifying an excipient or excipients contributing to adverse events in an individual comprising comparing adverse events associated with repeated daily administration of a drug pharmaceutical formulation containing an excipient or excipients to the adverse events associated with repeated daily administration of a drug pharmaceutical formulation having the same active ingredient but lacking said excipient or excipients.
A method of avoiding excipient stacking in an individual comprising administrating to said individual one or more pharmaceutical formulations lacking an excipient or excipients previously identified as contributing to adverse events.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of identifying an excipient or excipients contributing to adverse events in a non-human animal comprising comparing adverse events associated with co-administration of two or more drug pharmaceutical formulations having at least one common excipient to the adverse events associated with co-administration of two or more drug pharmaceutical formulations lacking said common excipient.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.